Dr. Anwer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9500 Euclid Ave
Cleveland, OH 44195Phone+1 216-444-2200Fax+1 216-444-9423
Summary
- Dr. Faiz Anwer is an oncologist in Cleveland, OH and is affiliated with Cleveland Clinic Taussig Cancer Center. He specializes in hematologic oncology.
Education & Training
- University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 2009 - 2012
- UPMC Medical EducationResidency, Internal Medicine, 2004 - 2007
- Rawalpindi Medical CollegeClass of 1998
Certifications & Licensure
- AZ State Medical License 2007 - 2026
- CA State Medical License 2018 - 2026
- IL State Medical License 2024 - 2026
- NC State Medical License 2024 - 2026
- NY State Medical License 2024 - 2026
- PA State Medical License 2007 - 2026
- IN State Medical License 2024 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnos Start of enrollment: 2011 Jan 01
- Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
- Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) Start of enrollment: 2019 Sep 23
Publications & Presentations
PubMed
- Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study.Majid Jaberi-Douraki, Xuan Xu, Danai Dima, Sikander Ailawadhi, Faiz Anwer
Blood Cancer Journal. 2024-12-20 - 2 citationsBispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.Maximilian Merz, Danai Dima, Hamza Hashmi, Nausheen Ahmed, Friedrich Stölzel
Blood Cancer Journal. 2024-12-05 - Rare case of wtTTR amyloidosis and MGUS in a patient with lung adenocarcinoma.Ahmad Safdar, Faiz Anwer
BMJ Case Reports. 2024-12-02
Abstracts/Posters
- Rapid Infusion Daratumumab Is Safe in Patients with AL AmyloidosisFaiz Anwer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple MyelomaFaiz Anwer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary EraFaiz Anwer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- A Network Meta-Analysis of Clinical Trials Assessing Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Among Young Adults2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Gene Therapy for Thalassemia and Sickle Cell Anemia Poses Acceptable Toxicity and Efficacy: Clinical Outcomes in Forty-Seven Cases2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Pomalidomide Based Regimens for Treatment of Relapsed Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- Management of Primary Plasma Cell Leukemia Remains Challenging Even in the Era of Novel AgentsFebruary 26th, 2021
- Multiple Myeloma: Choosing Your PathDecember 18th, 2020
- COVID-19 and Its Psychological Impacts on Healthcare Staff – A Multi-Centric Comparative Cross-Sectional StudyNovember 28th, 2020
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: